Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
Ontology highlight
ABSTRACT: Combinations of topoisomerase inhibitors I and II have been found to synergistically inhibit cancer cell growth in vitro, yet clinical studies of these types of combinations have not progressed beyond phase II trials. The results of clinical combinations of topoisomerase (top) I and II inhibitors typically fall within one of two categories: little to no improvement in therapeutic efficacy, or augmented toxicity compared to the single drug counterparts. Hence, despite the promising activity of top I and II inhibitor combinations in vitro, their clinical applicability has not been realized. Here, we report the use of polymer-drug conjugates as a means to co-deliver synergistic doses of top I and II inhibitors camptothecin (CPT) and doxorubicin (DOX) to tumors in vivo in a 4T1 breast cancer m
SUBMITTER: Camacho KM
PROVIDER: S-EPMC4470752 | biostudies-literature | 2015 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA